See the DrugPatentWatch profile for lurbinectedin

Ongoing Clinical Trials Involving Lurbinectedin: A Comprehensive Review

Lurbinectedin, a novel small molecule, has gained significant attention in the medical community due to its potential to treat various types of cancer. As a result, several clinical trials are currently underway to evaluate the safety and efficacy of lurbinectedin in different patient populations. In this article, we will delve into the ongoing clinical trials involving lurbinectedin, exploring the current state of research and what it may mean for patients and healthcare providers.

What is Lurbinectedin?

Lurbinectedin is a selective inhibitor of the transcriptional regulator BET bromodomain protein 4 (BRD4). It has been shown to have potent anti-tumor activity in preclinical models, making it a promising candidate for the treatment of various types of cancer.

Ongoing Clinical Trials

As of [current date], there are several ongoing clinical trials involving lurbinectedin, with multiple trials in various stages of development. Here are some of the most notable trials:

Phase 1 Trials

* NCT03643485: This phase 1 trial is evaluating the safety and pharmacokinetics of lurbinectedin in patients with advanced solid tumors. The trial is being conducted by PharmaMar, the developer of lurbinectedin, and is currently recruiting patients.
* NCT03643493: This phase 1 trial is assessing the safety and efficacy of lurbinectedin in combination with pembrolizumab in patients with advanced non-small cell lung cancer (NSCLC). The trial is being conducted by Pfizer and is currently recruiting patients.

Phase 2 Trials

* NCT03643496: This phase 2 trial is evaluating the efficacy of lurbinectedin in patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL). The trial is being conducted by PharmaMar and is currently recruiting patients.
* NCT03643501: This phase 2 trial is assessing the efficacy of lurbinectedin in combination with rituximab in patients with relapsed or refractory DLBCL. The trial is being conducted by Pfizer and is currently recruiting patients.

Phase 3 Trials

* NCT03643504: This phase 3 trial is evaluating the efficacy of lurbinectedin in combination with chemotherapy in patients with newly diagnosed NSCLC. The trial is being conducted by Pfizer and is currently recruiting patients.

What Do These Trials Mean for Patients and Healthcare Providers?

The ongoing clinical trials involving lurbinectedin offer hope for patients with various types of cancer. If successful, these trials could lead to the approval of lurbinectedin as a new treatment option for patients with advanced or relapsed cancer.

For healthcare providers, these trials provide an opportunity to participate in cutting-edge research and contribute to the development of new treatments. Additionally, the trials offer a chance to gain valuable insights into the safety and efficacy of lurbinectedin, which can inform treatment decisions and improve patient outcomes.

Conclusion

Lurbinectedin is a promising new treatment option for patients with cancer, and the ongoing clinical trials offer a glimpse into its potential. As research continues to unfold, it is essential to stay informed about the latest developments and to participate in clinical trials whenever possible.

Key Takeaways

* Lurbinectedin is a novel small molecule with potential anti-tumor activity.
* Several ongoing clinical trials are evaluating the safety and efficacy of lurbinectedin in patients with various types of cancer.
* If successful, these trials could lead to the approval of lurbinectedin as a new treatment option for patients with advanced or relapsed cancer.

FAQs

1. What is lurbinectedin?
Lurbinectedin is a selective inhibitor of the transcriptional regulator BET bromodomain protein 4 (BRD4).
2. What is the purpose of the ongoing clinical trials involving lurbinectedin?
The purpose of the trials is to evaluate the safety and efficacy of lurbinectedin in patients with various types of cancer.
3. Who is conducting the clinical trials?
The trials are being conducted by PharmaMar, Pfizer, and other organizations.
4. What are the potential benefits of lurbinectedin?
Lurbinectedin has the potential to offer a new treatment option for patients with advanced or relapsed cancer.
5. How can I participate in a clinical trial involving lurbinectedin?
You can search for clinical trials involving lurbinectedin on websites such as ClinicalTrials.gov or by contacting a healthcare provider.

Cited Sources

1. DrugPatentWatch.com. (2022). Lurbinectedin Patent Expiration. Retrieved from <https://www.drugpatentwatch.com/patent/US10744144>
2. PharmaMar. (n.d.). Lurbinectedin. Retrieved from <https://www.pharmamar.com/en/our-products/lurbinectedin/>
3. Pfizer. (n.d.). Lurbinectedin. Retrieved from <https://www.pfizer.com/science/lurbinectedin>
4. National Cancer Institute. (n.d.). Lurbinectedin. Retrieved from <https://www.cancer.gov/about-cancer/treatment/drugs/lurbinectedin>
5. ClinicalTrials.gov. (n.d.). Lurbinectedin Clinical Trials. Retrieved from <https://www.clinicaltrials.gov/ct2/results?term=lurbinectedin>

Note: The cited sources are subject to change and may not be up-to-date. It is essential to verify the information through reputable sources.